Allarity Therapeutics Welcomes New Chief Financial Officer
Allarity Therapeutics, Inc. (NASDAQ: ALLR), a prominent clinical-stage pharmaceutical firm, has exciting news regarding its leadership team. The company has officially appointed Alex Epshinsky as its new Chief Financial Officer (CFO). This decision supports Allarity's important mission to create innovative cancer treatments that are sensitive to patient needs.
Introducing Alex Epshinsky
With almost ten years of experience in finance specifically geared toward the biotech sector, Alex Epshinsky is in a strong position to make meaningful contributions to Allarity’s future. Epshinsky is a Chartered Public Accountant (CPA), and his journey includes significant roles such as the controller at Avenue Therapeutics, as well as key financial positions at Aruvant and Turnstone Biologics. He holds a Master of Science in Accounting from Kean University and a Bachelor of Arts in Economics from Rutgers University.
Key Responsibilities and Goals
With Epshinsky's financial leadership experience, he will be crucial as Allarity advances its landmark drug, stenoparib, which is a promising PARP inhibitor used for treating advanced recurrent ovarian cancer. His expertise will help strengthen the company’s financial framework and refine its operational strategies.
Statements from the Leadership
Thomas Jensen, the CEO of Allarity Therapeutics, shared his excitement about Epshinsky joining the team. He stated, "We are thrilled to welcome Alex to our team at such a dynamic moment for Allarity. His extensive financial management experience within the biotech sphere, particularly in oncology, will help guide our efforts as we advance stenoparib and pursue our operational goals.”
A New Direction
Epshinsky shared his thoughts, saying, "Joining Allarity is an exciting opportunity. I look forward to working closely with the leadership team in solidifying the financial groundwork that will allow us to innovate for patients who are battling ovarian cancer." As Allarity strives to improve cancer treatments, it prioritizes the development of customized therapies.
Inducement Grants for the New CFO
As part of Epshinsky's onboarding process, Allarity has granted him inducement awards comprising 55,555 restricted stock units (RSUs). These grants serve as a significant incentive for his employment and received validation from Allarity's Board of Directors. The vested stock awards will be released in equal one-third installments annually, contingent upon his continuing employment with the organization.
About Stenoparib: A Potential Game-Changer
Stenoparib is an innovative oral therapy that acts as a dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2. The current emphasis on tankyrases as vital targets for cancer treatment arises from their role in the Wnt signaling pathway, which is critical in the development of cancer. The unique design of stenoparib aims to interfere with this pathway, providing hope for patients dealing with advanced ovarian cancer.
Allarity Therapeutics: A Commitment to Cancer Care
Allarity Therapeutics, Inc. (NASDAQ: ALLR) continues to establish itself as a key player in the biopharmaceutical field. The company is committed to personalizing cancer treatments through its proprietary DRP® companion diagnostic, which is already being utilized in ongoing clinical trials like NCT03878849, targeting advanced ovarian cancer. Based in the U.S. and with a research center in Denmark, Allarity is focused on addressing pressing unmet medical needs in cancer therapies.
Frequently Asked Questions
What role has Alex Epshinsky taken on at Allarity Therapeutics?
Alex Epshinsky has been appointed as the Chief Financial Officer (CFO) of Allarity Therapeutics, bringing significant experience from the biotech industry.
What are the inducement grants issued to Alex Epshinsky?
Epshinsky received 55,555 restricted stock units (RSUs) as part of his employment inducement, which will vest over three years.
What is the focus of Allarity Therapeutics?
Allarity is focused on developing personalized cancer treatments, specifically advancing stenoparib, a novel therapy for advanced ovarian cancer.
Where does Allarity Therapeutics operate?
Allarity has its headquarters in the U.S. and also operates a research facility in Denmark.
How does stenoparib work?
Stenoparib is a dual-targeted inhibitor that affects PARP1/2 and Tankyrases, targeting pathways critical to cancer progression.
